



Alzinova presents at several conferences and investor meetings in the spring of 2023

Alzinova AB (publ) ("Alzinova" or the "Company") will present the Company at both Swedish and international investor meetings and conferences during the spring of 2023. In March, the Alzheimer's conference AD/PD™ will take place in Gothenburg, bringing together international industry players and researchers from academia. In June, the Biotech International Convention, ("US Bio") will take place, which is an important American business conference for partner meetings. During the event, the Company will present its ALZ-101 vaccine candidate and ALZ-201 antibody to potential partners. During the spring, Alzinova will also present the Company to investors at various capital market events.

Alzinova's strategy, to develop an effective and safe treatment for Alzheimer's disease that targets the toxic forms of amyloid beta, the oligomers, has been gaining interest. Preclinical data has documented "best in class" potential and clinical results from other actors in the field strengthens the Company's strategy. The Company will increase its participation at conferences, with the goal of establishing global partnerships.

International conferences:

AD/PD™ - International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, March 28 – April 1

AD/PD™ is an international conference on neurodegenerative diseases held in Gothenburg from 28 March to 1 April. The AD/PD™ conference has become a major event in the field of neurodegenerative diseases, attracting leading medical and scientific experts from around the world. AD/PD™ is an annual meeting focusing on advances in research and treatment for Alzheimer's, Parkinson's disease and other related neurological disorders. Alzinova will be there to network and present the Company's pharmaceutical projects to Key Opinion Leaders, potential licensees and partners. In conjunction with the conference, Alzinova's Chief Scientific Officer Anders Sandberg will present a scientific poster on the Company's vaccine candidate ALZ-101. Read more here: <https://adpd.kenes.com/>

Biotech International Convention - US BIO, June 5 – 8

The BIO International Convention is the world's largest meeting place for pharmaceutical and biotechnology companies, attracting over 14,000 leaders in the biotechnology and pharmaceutical industries to a week of intensive networking to discover new opportunities, enable collaborative and partner discussions and investor meetings. In total, over 3,000 companies participate from more than 30 countries. Alzinova's CEO, Kristina Torfgård and Business Development Director, Sebastian Hansson will meet potential partners from their global network in the pharmaceutical industry and establish new contacts with a focus on presenting and promoting the Company's pharmaceutical projects. Read more here: <https://www.bio.org/events/bio-international-convention>



For investors:

Redeye Theme: Alzheimer's disease, March 15

Drug development in the field of Alzheimer's disease is an ongoing hot topic and society is now facing an important paradigm shift with the commercialisation of the first disease-modifying therapies. Redeye has invited Alzinova and two other companies - three prominent Swedish Alzheimer's companies - to a panel discussion to talk about the science behind their drug candidates, the remaining need and what it will take to successfully launch a new generation of Alzheimer's drugs. CEO Kristina Torfgård will participate in the panel. Read more here: <https://www.redeye.se/events/875025/redeye-alzheimer-seminar>

Mangold Insight Investor Day – Life Science, March 22

At Mangold Insight's investor day, Alzinova's CEO Kristina Torfgård will present the Company and its latest developments. For more information: <https://mangold.se/evenemang/mangold-insight-investerardag-22-mars/>

Redeye Investor Forum Malmö, March 30

Redeye Investor Forum is a live broadcast where different companies give a 12-minute presentation followed by an 8-minute Q&A session moderated by Redeye analysts. Kristina Torfgård, CEO, will be in Malmö to present Alzinova's business. You can ask your questions directly to Alzinova during the live broadcast in the question form available on the event page: <https://www.redeye.se/events/870674/investor-forum-malmo-5>

Redeye Investor Forum Gothenburg, April 20

CEO Kristina Torfgård presents at Redeye Investor Forum in Gothenburg on 20 April. The event is a live broadcast where different companies will give a 12-minute presentation followed by an 8-minute Q&A session moderated by Redeye's analysts. You can ask your questions directly to Alzinova during the live broadcast in the question form available on the event page: <https://www.redeye.se/events/870525/investor-forum-goteborg-16>

For more information, please contact:

Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.



About Alzinova

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A β CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: www.alzinova.com

Attachments

Alzinova presents at several conferences and investor meetings in the spring of 2023